Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation
Background To determine X‐ray repair cross‐complementing 1 gene (XRCC‐1) Arg194Trp polymorphism as bio‐predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin‐based chemoradiation (CRT). Methods A total of 150 patients were enrolled in this prospective study...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2020-05, Vol.42 (5), p.1045-1056 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1056 |
|---|---|
| container_issue | 5 |
| container_start_page | 1045 |
| container_title | Head & neck |
| container_volume | 42 |
| creator | Raturi, Vijay Hojo, Hidehiro Bhatt, M. L. B. Suhel, Mohammad Wu, Chen‐Ta Bei, Yanping Nakamura, Masaki Okumura, Masayuki Zhang, Haiqin Parmar, Devendra Badajena, Avinash Singh, Rahul Kumar, Saurabh Katiyar, Tridev Gaur, Jalaj |
| description | Background
To determine X‐ray repair cross‐complementing 1 gene (XRCC‐1) Arg194Trp polymorphism as bio‐predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin‐based chemoradiation (CRT).
Methods
A total of 150 patients were enrolled in this prospective study. XRCC‐1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiation‐induced toxicity (ARIT).
Results
A significant correlation of skin (P‐ .04) and oral mucosal ARIT (P‐ .01) was noticed in the XRCC‐1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance (P‐ .08). With 33 months of median follow‐up, 2‐year progression‐free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% (P‐ .066) and 50.6% vs 62.2% (P‐ .12).
Conclusion
XRCC‐1 polymorphic variants have significantly higher grade of >2 ARIT and may have improved trend for treatment response and PFS. |
| doi_str_mv | 10.1002/hed.26083 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2392424423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2392424423</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-afb41f5ea6c8b2135078301a82fe05cc19fc02507c729c0cc5cc04fc9501ce4a3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EoqWw4AWQJVZdpL3-yWSyrIZCkSpRVUViFzk3zowrxw52Mmh2fQSehUfiSbjTaZcsrGsdfTr35zD2XsCZAJDnG9udyQUs1Qt2LKCuClC6ern_a1UoqPQRe5PzPQCohZav2ZESdV1pJY_Zn5sU82hxclvL7db42UwuBh57_uN2tfr78Fvwi7QWtb5LIx-j3w0xjRuXB24yb10kYky2czjFxHt66F1waDyP84RxsNwF7iMJfsdNtzUBbce9SbuwtkThXkh8Dp1N6-jCmqPLo6cpAlm3JhONG0tdTeceZ3vLXvXGZ_vuqZ6w758v71ZXxfW3L19XF9cFqlKpwvStFn1pzQKXrRSqhGqpQJil7C2UiKLuESSpWMkaAZE00D3WJQi02qgT9vHgO6b4c7Z5au7jnAK1bKSqpZZaS0XU6YFCOmROtm_G5AZarxHQ7NNpKJ3mMR1iPzw5zu1A6jP5HAcB5wfgl_N293-n5ury08HyH9_8n6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2392424423</pqid></control><display><type>article</type><title>Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Raturi, Vijay ; Hojo, Hidehiro ; Bhatt, M. L. B. ; Suhel, Mohammad ; Wu, Chen‐Ta ; Bei, Yanping ; Nakamura, Masaki ; Okumura, Masayuki ; Zhang, Haiqin ; Parmar, Devendra ; Badajena, Avinash ; Singh, Rahul ; Kumar, Saurabh ; Katiyar, Tridev ; Gaur, Jalaj</creator><creatorcontrib>Raturi, Vijay ; Hojo, Hidehiro ; Bhatt, M. L. B. ; Suhel, Mohammad ; Wu, Chen‐Ta ; Bei, Yanping ; Nakamura, Masaki ; Okumura, Masayuki ; Zhang, Haiqin ; Parmar, Devendra ; Badajena, Avinash ; Singh, Rahul ; Kumar, Saurabh ; Katiyar, Tridev ; Gaur, Jalaj</creatorcontrib><description>Background
To determine X‐ray repair cross‐complementing 1 gene (XRCC‐1) Arg194Trp polymorphism as bio‐predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin‐based chemoradiation (CRT).
Methods
A total of 150 patients were enrolled in this prospective study. XRCC‐1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiation‐induced toxicity (ARIT).
Results
A significant correlation of skin (P‐ .04) and oral mucosal ARIT (P‐ .01) was noticed in the XRCC‐1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance (P‐ .08). With 33 months of median follow‐up, 2‐year progression‐free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% (P‐ .066) and 50.6% vs 62.2% (P‐ .12).
Conclusion
XRCC‐1 polymorphic variants have significantly higher grade of >2 ARIT and may have improved trend for treatment response and PFS.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.26083</identifier><identifier>PMID: 31997432</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Antineoplastic Combined Chemotherapy Protocols ; Chemoradiotherapy ; Chemotherapy ; Cisplatin ; cisplatin‐based chemoradiation ; Gene polymorphism ; Genotyping ; Head and neck ; Head and Neck Neoplasms - genetics ; Head and Neck Neoplasms - therapy ; Humans ; Laryngeal cancer ; Laryngeal Neoplasms - genetics ; Laryngeal Neoplasms - therapy ; locally advanced laryngeal squamous cell cancer ; Mucosa ; Patients ; polymerase chain reaction ; Polymorphism ; Prospective Studies ; single nucleotide polymorphism ; Squamous cell carcinoma ; Toxicity ; X-ray Repair Cross Complementing Protein 1 - genetics ; X‐ray repair cross‐complementing 1 gene</subject><ispartof>Head & neck, 2020-05, Vol.42 (5), p.1045-1056</ispartof><rights>2020 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-afb41f5ea6c8b2135078301a82fe05cc19fc02507c729c0cc5cc04fc9501ce4a3</citedby><cites>FETCH-LOGICAL-c3533-afb41f5ea6c8b2135078301a82fe05cc19fc02507c729c0cc5cc04fc9501ce4a3</cites><orcidid>0000-0002-1687-1957</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.26083$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.26083$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31997432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raturi, Vijay</creatorcontrib><creatorcontrib>Hojo, Hidehiro</creatorcontrib><creatorcontrib>Bhatt, M. L. B.</creatorcontrib><creatorcontrib>Suhel, Mohammad</creatorcontrib><creatorcontrib>Wu, Chen‐Ta</creatorcontrib><creatorcontrib>Bei, Yanping</creatorcontrib><creatorcontrib>Nakamura, Masaki</creatorcontrib><creatorcontrib>Okumura, Masayuki</creatorcontrib><creatorcontrib>Zhang, Haiqin</creatorcontrib><creatorcontrib>Parmar, Devendra</creatorcontrib><creatorcontrib>Badajena, Avinash</creatorcontrib><creatorcontrib>Singh, Rahul</creatorcontrib><creatorcontrib>Kumar, Saurabh</creatorcontrib><creatorcontrib>Katiyar, Tridev</creatorcontrib><creatorcontrib>Gaur, Jalaj</creatorcontrib><title>Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
To determine X‐ray repair cross‐complementing 1 gene (XRCC‐1) Arg194Trp polymorphism as bio‐predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin‐based chemoradiation (CRT).
Methods
A total of 150 patients were enrolled in this prospective study. XRCC‐1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiation‐induced toxicity (ARIT).
Results
A significant correlation of skin (P‐ .04) and oral mucosal ARIT (P‐ .01) was noticed in the XRCC‐1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance (P‐ .08). With 33 months of median follow‐up, 2‐year progression‐free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% (P‐ .066) and 50.6% vs 62.2% (P‐ .12).
Conclusion
XRCC‐1 polymorphic variants have significantly higher grade of >2 ARIT and may have improved trend for treatment response and PFS.</description><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>cisplatin‐based chemoradiation</subject><subject>Gene polymorphism</subject><subject>Genotyping</subject><subject>Head and neck</subject><subject>Head and Neck Neoplasms - genetics</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Humans</subject><subject>Laryngeal cancer</subject><subject>Laryngeal Neoplasms - genetics</subject><subject>Laryngeal Neoplasms - therapy</subject><subject>locally advanced laryngeal squamous cell cancer</subject><subject>Mucosa</subject><subject>Patients</subject><subject>polymerase chain reaction</subject><subject>Polymorphism</subject><subject>Prospective Studies</subject><subject>single nucleotide polymorphism</subject><subject>Squamous cell carcinoma</subject><subject>Toxicity</subject><subject>X-ray Repair Cross Complementing Protein 1 - genetics</subject><subject>X‐ray repair cross‐complementing 1 gene</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS0EoqWw4AWQJVZdpL3-yWSyrIZCkSpRVUViFzk3zowrxw52Mmh2fQSehUfiSbjTaZcsrGsdfTr35zD2XsCZAJDnG9udyQUs1Qt2LKCuClC6ern_a1UoqPQRe5PzPQCohZav2ZESdV1pJY_Zn5sU82hxclvL7db42UwuBh57_uN2tfr78Fvwi7QWtb5LIx-j3w0xjRuXB24yb10kYky2czjFxHt66F1waDyP84RxsNwF7iMJfsdNtzUBbce9SbuwtkThXkh8Dp1N6-jCmqPLo6cpAlm3JhONG0tdTeceZ3vLXvXGZ_vuqZ6w758v71ZXxfW3L19XF9cFqlKpwvStFn1pzQKXrRSqhGqpQJil7C2UiKLuESSpWMkaAZE00D3WJQi02qgT9vHgO6b4c7Z5au7jnAK1bKSqpZZaS0XU6YFCOmROtm_G5AZarxHQ7NNpKJ3mMR1iPzw5zu1A6jP5HAcB5wfgl_N293-n5ury08HyH9_8n6w</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Raturi, Vijay</creator><creator>Hojo, Hidehiro</creator><creator>Bhatt, M. L. B.</creator><creator>Suhel, Mohammad</creator><creator>Wu, Chen‐Ta</creator><creator>Bei, Yanping</creator><creator>Nakamura, Masaki</creator><creator>Okumura, Masayuki</creator><creator>Zhang, Haiqin</creator><creator>Parmar, Devendra</creator><creator>Badajena, Avinash</creator><creator>Singh, Rahul</creator><creator>Kumar, Saurabh</creator><creator>Katiyar, Tridev</creator><creator>Gaur, Jalaj</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-1687-1957</orcidid></search><sort><creationdate>202005</creationdate><title>Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation</title><author>Raturi, Vijay ; Hojo, Hidehiro ; Bhatt, M. L. B. ; Suhel, Mohammad ; Wu, Chen‐Ta ; Bei, Yanping ; Nakamura, Masaki ; Okumura, Masayuki ; Zhang, Haiqin ; Parmar, Devendra ; Badajena, Avinash ; Singh, Rahul ; Kumar, Saurabh ; Katiyar, Tridev ; Gaur, Jalaj</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-afb41f5ea6c8b2135078301a82fe05cc19fc02507c729c0cc5cc04fc9501ce4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>cisplatin‐based chemoradiation</topic><topic>Gene polymorphism</topic><topic>Genotyping</topic><topic>Head and neck</topic><topic>Head and Neck Neoplasms - genetics</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Humans</topic><topic>Laryngeal cancer</topic><topic>Laryngeal Neoplasms - genetics</topic><topic>Laryngeal Neoplasms - therapy</topic><topic>locally advanced laryngeal squamous cell cancer</topic><topic>Mucosa</topic><topic>Patients</topic><topic>polymerase chain reaction</topic><topic>Polymorphism</topic><topic>Prospective Studies</topic><topic>single nucleotide polymorphism</topic><topic>Squamous cell carcinoma</topic><topic>Toxicity</topic><topic>X-ray Repair Cross Complementing Protein 1 - genetics</topic><topic>X‐ray repair cross‐complementing 1 gene</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raturi, Vijay</creatorcontrib><creatorcontrib>Hojo, Hidehiro</creatorcontrib><creatorcontrib>Bhatt, M. L. B.</creatorcontrib><creatorcontrib>Suhel, Mohammad</creatorcontrib><creatorcontrib>Wu, Chen‐Ta</creatorcontrib><creatorcontrib>Bei, Yanping</creatorcontrib><creatorcontrib>Nakamura, Masaki</creatorcontrib><creatorcontrib>Okumura, Masayuki</creatorcontrib><creatorcontrib>Zhang, Haiqin</creatorcontrib><creatorcontrib>Parmar, Devendra</creatorcontrib><creatorcontrib>Badajena, Avinash</creatorcontrib><creatorcontrib>Singh, Rahul</creatorcontrib><creatorcontrib>Kumar, Saurabh</creatorcontrib><creatorcontrib>Katiyar, Tridev</creatorcontrib><creatorcontrib>Gaur, Jalaj</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raturi, Vijay</au><au>Hojo, Hidehiro</au><au>Bhatt, M. L. B.</au><au>Suhel, Mohammad</au><au>Wu, Chen‐Ta</au><au>Bei, Yanping</au><au>Nakamura, Masaki</au><au>Okumura, Masayuki</au><au>Zhang, Haiqin</au><au>Parmar, Devendra</au><au>Badajena, Avinash</au><au>Singh, Rahul</au><au>Kumar, Saurabh</au><au>Katiyar, Tridev</au><au>Gaur, Jalaj</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2020-05</date><risdate>2020</risdate><volume>42</volume><issue>5</issue><spage>1045</spage><epage>1056</epage><pages>1045-1056</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
To determine X‐ray repair cross‐complementing 1 gene (XRCC‐1) Arg194Trp polymorphism as bio‐predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin‐based chemoradiation (CRT).
Methods
A total of 150 patients were enrolled in this prospective study. XRCC‐1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiation‐induced toxicity (ARIT).
Results
A significant correlation of skin (P‐ .04) and oral mucosal ARIT (P‐ .01) was noticed in the XRCC‐1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance (P‐ .08). With 33 months of median follow‐up, 2‐year progression‐free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% (P‐ .066) and 50.6% vs 62.2% (P‐ .12).
Conclusion
XRCC‐1 polymorphic variants have significantly higher grade of >2 ARIT and may have improved trend for treatment response and PFS.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31997432</pmid><doi>10.1002/hed.26083</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-1687-1957</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2020-05, Vol.42 (5), p.1045-1056 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_journals_2392424423 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols Chemoradiotherapy Chemotherapy Cisplatin cisplatin‐based chemoradiation Gene polymorphism Genotyping Head and neck Head and Neck Neoplasms - genetics Head and Neck Neoplasms - therapy Humans Laryngeal cancer Laryngeal Neoplasms - genetics Laryngeal Neoplasms - therapy locally advanced laryngeal squamous cell cancer Mucosa Patients polymerase chain reaction Polymorphism Prospective Studies single nucleotide polymorphism Squamous cell carcinoma Toxicity X-ray Repair Cross Complementing Protein 1 - genetics X‐ray repair cross‐complementing 1 gene |
| title | Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A23%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20evaluation%20of%20XRCC%E2%80%901%20Arg194Trp%20polymorphism%20as%20bio%E2%80%90predictor%20for%20clinical%20outcome%20in%20locally%20advanced%20laryngeal%20cancer%20undergoing%20cisplatin%E2%80%90based%20chemoradiation&rft.jtitle=Head%20&%20neck&rft.au=Raturi,%20Vijay&rft.date=2020-05&rft.volume=42&rft.issue=5&rft.spage=1045&rft.epage=1056&rft.pages=1045-1056&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.26083&rft_dat=%3Cproquest_cross%3E2392424423%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2392424423&rft_id=info:pmid/31997432&rfr_iscdi=true |